Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
1.698 Leser
Artikel bewerten:
(2)

3M and Eko confirm launch of new Littmann CORE Digital Stethoscope in Europe

Finanznachrichten News

Bringing together science, technology, and comprehensive solutions to redefine what's possible in healthcare

BRACKNELL, England, June 10, 2021 /PRNewswire/ -- As the world of healthcare and its dependence on auscultation continues to evolve, digital technology is being introduced to meet the advancing demands of the industry. To meet these changing needs, 3M Littmann Stethoscopes and Eko formed a collaboration that has married best-in-class 3M Littmann stethoscope technology with advanced Eko digital innovations. The 3M Littmann CORE Digital Stethoscope, which has quickly become a popular choice among physicians in the United States over the last six months1, has launched in the United Kingdom & Ireland.

The new 3M Littmann CORE Digital Stethoscope offers clinicians access to both analogue and digital auscultation options and can connect to Eko's software app via Bluetooth. The Littmann CORE Stethoscope offers access to additional benefits including:

  • User can switch from analogue listening to digital
  • Amplification2 up to 40x at peak frequency, versus mechanical
  • Seven sound amplification levels
  • Provides active noise cancelation
  • Connects to Eko software on a smart device to visualise, record, store & share auscultation assessment

"3M Littmann Stethoscopes is a pioneer in auscultation innovation and quality, and today, we are introducing our most advanced stethoscope yet to Europe," said Kristi Barnett, senior director, 3M Medical Devices. "The new 3M Littmann CORE Digital Stethoscope combines the superior acoustics of the Littmann Cardiology IV Stethoscope with Eko's digital technology and software to aid and enhance a clinician's auscultation assessments."

The collaboration between 3M Littmann Stethoscopes and Eko brings together two innovative companies that are focused on delivering comprehensive health care solutions to drive better patient outcomes.

"For clinicians, listening is a gateway to making critical diagnoses. Being able to confidently assess heart and lung sounds helps ensure the best cardiac and pulmonary care possible," said Connor Landgraf, co-founder and CEO, Eko. "Partnering with 3M Littmann Stethoscopes allows us to incorporate the power of our digital and machine learning technology alongside the stethoscope trusted by millions of clinicians worldwide, which can help impact patient outcomes and quality of care in Europe. Combining the 3M Littmann CORE Digital Stethoscope with the Eko software platform helps clinicians elevate cardiopulmonary care to a whole new level."

The combination allows a healthcare professional located outside of secondary care, treating patients in their homes or in a community practice, to have access to cutting-edge clinical decision support. Also available is the ability to connect directly to their consultant in secondary care, mitigating the need for the patient to make unnecessary travel into traditional clinic environments.

In the midst of a global pandemic, and the highly challenging need to assess and monitor COVID patients, this can be leveraged as a means to protect healthcare professionals, whilst providing the highest standards of care.

The very same function that allows the streaming of the sounds from the Littmann CORE Stethoscope via the Eko app, and to a variety of wired and Bluetooth headphones, can also facilitate communication to several hearing aid models, providing a long-awaited solution for many hearing-impaired healthcare professionals.

For more information on the 3M Littmann CORE Stethoscope or where to buy, please visit: www.littmann.co.uk/CORE. For more on Eko software, please visit ekohealth.com/platform.

1Average product rating of 4.6 out of 5 stars on Amazon in the United States as of March 10, 2021.
2Up to 40x amplification based on comparison of analogue versus electronically assisted amplified listening with maximum volume at the peak frequency (125 Hz).

About 3M
At 3M, we apply science in collaborative ways to improve lives daily as our employees connect with customers all around the world. Learn more about 3M's creative solutions to global challenges at www.3M.com or on Twitter @3M or @3MNews.

About Eko

Eko, a cardiopulmonary digital health company, is elevating the way clinicians detect and monitor cardiac and respiratory disease by bringing together advanced sensors, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by tens of thousands of clinicians treating millions of patients around the world, in-person and through telehealth. The company is headquartered in Oakland, California, with investments from Highland Capital Partners, Questa Capital, Artis Ventures, NTTVC, DigiTx Partners, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Logo - https://mma.prnewswire.com/media/1343410/3M_Logo.jpg

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.